These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25750339)

  • 1. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer.
    Ishikawa H; Hashimoto T; Moriwaki T; Hyodo I; Hisakura K; Terashima H; Ohkohchi N; Ohno T; Makishima H; Mizumoto M; Ohnishi K; Okumura T; Sakurai H
    Anticancer Res; 2015 Mar; 35(3):1757-62. PubMed ID: 25750339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction].
    Niho S; Motegi A; Akimoto T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):144-7. PubMed ID: 25743132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
    Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
    Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer.
    Takada A; Nakamura T; Takayama K; Makita C; Suzuki M; Azami Y; Kato T; Tsukiyama I; Hareyama M; Kikuchi Y; Daimon T; Toyomasu Y; Ii N; Nomoto Y; Sakuma H; Fuwa N
    Cancer Med; 2016 Mar; 5(3):506-15. PubMed ID: 26806272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
    Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
    Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperfractionated concomitant boost proton beam therapy for esophageal carcinoma.
    Mizumoto M; Sugahara S; Okumura T; Hashimoto T; Oshiro Y; Fukumitsu N; Nakahara A; Terashima H; Tsuboi K; Sakurai H
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e601-6. PubMed ID: 21511402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton beam therapy and concurrent chemotherapy for esophageal cancer.
    Lin SH; Komaki R; Liao Z; Wei C; Myles B; Guo X; Palmer M; Mohan R; Swisher SG; Hofstetter WL; Ajani JA; Cox JD
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e345-51. PubMed ID: 22417808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
    Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
    J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021).
    Nishimura Y; Hiraoka M; Koike R; Nakamatsu K; Itasaka S; Kawamura M; Negoro Y; Araki N; Ishikawa H; Fujii T; Mitsuhashi N
    Jpn J Clin Oncol; 2012 Sep; 42(9):807-12. PubMed ID: 22811410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer.
    Posner MC; Gooding WE; Lew JI; Rosenstein MM; Lembersky BC
    Surgery; 2001 Oct; 130(4):620-6; discussion 626-8. PubMed ID: 11602892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
    Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
    Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer.
    Hiroshima Y; Fukumitsu N; Saito T; Numajiri H; Murofushi KN; Ohnishi K; Nonaka T; Ishikawa H; Okumura T; Sakurai H
    Radiother Oncol; 2019 Jul; 136():37-43. PubMed ID: 31015127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.